Summit Therapeutics announced that its partner, Akeso Inc., reported positive updated overall survival (OS) data from the Phase III HARMONi-2 trial. The study showed that ivonescimab monotherapy demonstrated a statistically significant and clinically meaningful benefit compared to pembrolizumab monotherapy in patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC).
Key Details
- Overall Survival: Ivonescimab showed a median overall survival of 30.8 months compared to 22.6 months for pembrolizumab, an improvement of 8.2 months.
- Risk Reduction: The trial demonstrated a 27% reduction in the risk of death for patients treated with ivonescimab versus pembrolizumab (Hazard Ratio = 0.73; p=0.009).
- Context: The data is from a study conducted in China by Akeso. Summit is conducting a similar global Phase III study, HARMONi-7, evaluating ivonescimab in patients with PD-L1 high-expressing NSCLC.